PTC Company Profile (NASDAQ:PMTC)

About PTC (NASDAQ:PMTC)

PTC logoPTC Inc. is a global computer software and services company. The Company offers a portfolio of computer-aided design (CAD) modeling, product lifecycle management (PLM) and service lifecycle management (SLM) solutions for manufacturers to create, operate, and service products. It offers a suite of Internet of Things (IoT) solutions that enables its customers to connect, manage and analyze data, and create applications. Its segments include the Solutions Group, the IoT Group and Professional Services. The Solutions Group segment includes its CAD, PLM and SLM products. The IoT Group segment includes its IoT, analytics and augmented reality (AR) solutions. The Professional Services segment includes consulting, implementation and training business. Its IoT products include ThingWorx, KEPServerEX, Vuforia Studio and Vuforia. Its CAD products include Creo and Mathcad. Its PLM products include Windchill, Integrity, Navigate and Creo View. Its SLM products include Servigistics and Arbortext.

Industry, Sector and Symbol:
  • Sector: Technology
  • Industry: Application Software
  • Sub-Industry: Application Software
  • Symbol: NASDAQ:PMTC
  • CUSIP: 69370C10
  • Web: www.ptc.com/
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.35
  • P/E Growth: N/A
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -0.33%
  • Return on Equity: -0.45%
  • Return on Assets: -0.16%
 

Frequently Asked Questions for PTC (NASDAQ:PMTC)

What is PTC's stock symbol?

PTC trades on the NASDAQ under the ticker symbol "PMTC."

Where is PTC's stock going? Where will PTC's stock price be in 2017?

1 brokerages have issued 12 month price targets for PTC's stock. Their forecasts range from $64.00 to $64.00. On average, they anticipate PTC's stock price to reach $64.00 in the next twelve months. View Analyst Ratings for PTC.

Who are some of PTC's key competitors?

Who are PTC's key executives?

PTC's management team includes the folowing people:

  • Robert P. Schechter, Independent Chairman of the Board
  • James E. Heppelmann, President, Chief Executive Officer, Director
  • Andrew D. Miller CPA, Chief Financial Officer, Executive Vice President
  • Robert C. Gremley, Group President - Technology Platform Group
  • Craig Hayman, Chief Operating Officer, Group President - Solutions Group
  • Barry F. Cohen, Executive Vice President - Strategy
  • Matthew Cohen, Executive Vice President - Global Services
  • Anthony DiBona, Executive Vice President - Global Support
  • Aaron C. Von Staats, Corporate Vice President, General Counsel, Secretary
  • Janice Durbin Chaffin, Independent Director

How do I buy PTC stock?

Shares of PTC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC's stock price today?

One share of PTC stock can currently be purchased for approximately $32.58.


MarketBeat Community Rating for PTC (NASDAQ PMTC)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about PTC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for PTC (NASDAQ:PMTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $64.00 (96.44% upside)

Analysts' Ratings History for PTC (NASDAQ:PMTC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017WedbushReiterated RatingOutperform$62.00 -> $64.00N/AView Rating Details
11/26/2015Jefferies Group LLCLower Price TargetBuy$33.00 -> $25.00N/AView Rating Details
9/9/2015Sterne Agee CRTInitiated CoverageNeutral$35.00N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for PTC (NASDAQ:PMTC)
Earnings by Quarter for PTC (NASDAQ:PMTC)
Earnings History by Quarter for PTC (NASDAQ PMTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2013Q413$0.53$0.59$335.00 million$344.80 millionViewN/AView Earnings Details
7/24/2013Q3 2013$0.43$0.45$322.52 million$315.50 millionViewN/AView Earnings Details
4/24/2013Q2 2013$0.35$0.41$315.92 million$313.90 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.33$0.36$320.89 million$321.30 millionViewN/AView Earnings Details
10/31/2012Q412$0.48$0.50$330.78 million$325.00 millionViewN/AView Earnings Details
7/25/2012$0.30$0.37ViewN/AView Earnings Details
4/25/2012$0.27$0.30ViewN/AView Earnings Details
10/26/2011$0.43$0.47ViewN/AView Earnings Details
4/27/2011$0.25$0.26ViewN/AView Earnings Details
1/26/2011$0.26$0.22ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PTC (NASDAQ:PMTC)
Current Year EPS Consensus Estimate: $2.03 EPS
Next Year EPS Consensus Estimate: $2.27 EPS

Dividends

Dividend History for PTC (NASDAQ:PMTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for PTC (NASDAQ:PMTC)
Insider Trades by Quarter for PTC (NASDAQ:PMTC)
Insider Trades by Quarter for PTC (NASDAQ:PMTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2013Anthony DibonaEVPSell23,457$32.03$751,327.71View SEC Filing  
11/12/2013James HeppelmannCEOSell25,000$32.06$801,500.00View SEC Filing  
8/13/2013Barry CohenEVPSell59,999$28.08$1,684,771.92View SEC Filing  
8/5/2013Anthony DibonaEVPSell8,751$27.53$240,915.03View SEC Filing  
8/1/2013James E HeppelmannCEOSell39,999$27.77$1,110,772.23View SEC Filing  
8/1/2013Robert RanaldiEVPSell4,000$27.78$111,120.00View SEC Filing  
7/30/2013Marc DiouaneEVPSell11,126$26.73$297,397.98View SEC Filing  
5/10/2013Marc DiouaneEVPSell7,375$24.07$177,516.25View SEC Filing  
5/1/2013James E HeppelmannCEOSell40,000$23.61$944,400.00View SEC Filing  
5/1/2013Robert RanaldiEVPSell4,000$23.62$94,480.00View SEC Filing  
12/4/2012Donald K GriersonDirectorSell10,000$20.10$201,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for PTC (NASDAQ:PMTC)
Latest Headlines for PTC (NASDAQ:PMTC)
Source:
DateHeadline
americanbankingnews.com logoContrasting PTC (NASDAQ:PMTC) and SeaChange International (SEAC)
www.americanbankingnews.com - August 13 at 10:32 PM
americanbankingnews.com logoPTC's (PMTC) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - July 20 at 11:46 AM
feeds.benzinga.com logoPortola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma
feeds.benzinga.com - June 15 at 8:52 AM
seekingalpha.com logoPTC Therapeutics sees Emflaza net price of $35K annually per patient
seekingalpha.com - May 8 at 2:31 PM
americanbankingnews.com logoWedbush Reaffirms Outperform Rating for PTC Inc (PMTC)
www.americanbankingnews.com - April 26 at 6:20 PM
seekingalpha.com logoPTC Therapeutics CFO to exit
seekingalpha.com - April 10 at 4:25 PM
americanbankingnews.com logoPTC's (PMTC) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - April 7 at 6:25 PM
finance.yahoo.com logoCan BlackBerry Become The Next Security Superpower?
finance.yahoo.com - April 7 at 11:56 AM
finance.yahoo.com logoGadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin
finance.yahoo.com - April 7 at 11:56 AM
fool.com logoWhy PTC Therapeutics Dropped 25.3% in March
www.fool.com - April 7 at 8:47 AM
wsj.com logoWhy PTC's Revenue Still Raises Eyebrows
www.wsj.com - March 26 at 10:27 AM
seekingalpha.com logoA Deep Forensic Analysis Of PTC Provides Evidence Suggesting Misrepresentations And 50% - 60% Downside
seekingalpha.com - March 24 at 1:23 AM
seekingalpha.com logoA Deep Forensic Analysis Of PTC Provides Evidence Suggesting Misrepresentations And 50- 60% Downside
seekingalpha.com - March 23 at 3:16 PM
fool.com logoWhy PTC Therapeutics, Tellurian, and B&G Foods Slumped Today
www.fool.com - March 16 at 5:03 PM
seekingalpha.com logoFDA to review PTC's marketing application for DMD candidate Translarna under protest regulations; action date October 24; shares ahead 15% premarket
seekingalpha.com - March 6 at 8:57 AM
fool.com logoBad News Biotechs: What's Next for Juno and PTC Therapeutics?
www.fool.com - March 4 at 6:51 AM
fool.com logoWhy PTC Therapeutics Is Plunging Today
www.fool.com - March 2 at 1:52 PM
feeds.benzinga.com logoNicox announces the presentation of NCX 667 scientific data at AOPT 2017
feeds.benzinga.com - February 21 at 4:36 AM
wsj.com logoPTC's Revenue Puzzle Still Unsolved
www.wsj.com - January 19 at 5:04 PM
seekingalpha.com logoPTC's Translarna approved in Europe for another year
seekingalpha.com - January 9 at 8:41 PM
fool.com logoPTC Therapeutics, Inc. in 3 Charts
www.fool.com - December 7 at 4:43 PM
fool.com logoWhy PTC Therapeutics, Inc. Stock Rose 75.4% in November
www.fool.com - December 5 at 2:27 PM
fool.com logoWhat PTC Therapeutics' CFO Is Saying About Translarna's Conditional Approval
www.fool.com - November 12 at 7:48 AM
feeds.benzinga.com logoMid-Afternoon Market Update: Gold Futures Down 3.5%; PTC Therapeutics Shares Spike Higher
feeds.benzinga.com - November 11 at 3:19 PM
fool.com logoWhy PTC Therapeutics Is Rocketing 74% Today
www.fool.com - November 11 at 1:31 PM
seekingalpha.com logoEuropean advisory committee backs renewal of marketing authorization for PTC's Translarna; shares up 78% premarket
seekingalpha.com - November 11 at 9:38 AM
feeds.benzinga.com logoPTC Therapeutics Surges 88% On European Marketing Authorization
feeds.benzinga.com - November 11 at 9:19 AM
wsj.com logoA Trust-Me Story at Software Maker PTC
www.wsj.com - November 1 at 1:46 PM
seekingalpha.com logoPTC misses by $0.10, misses on revenue
seekingalpha.com - October 26 at 4:48 PM
wsj.com logoNew Sales Model Obscures Weakness at Software Maker
www.wsj.com - October 25 at 6:14 PM
seekingalpha.com logoPTC Therapeutics poised for $20M milestone from licensee Roche on advancement of mid-stage study of RG7916 in spinal muscular atrophy; shares ahead 4% premarket
seekingalpha.com - October 21 at 9:20 AM
investorplace.com logoWhy LendingClub Corp (LC), Devon Energy Corp (DVN) and PTC Therapeutics, Inc. (PTCT) Are 3 of Today’s Worst Stocks
investorplace.com - October 17 at 4:40 PM
fool.com logoWhy PTC Therapeutics, Inc. Is Crashing Today
www.fool.com - October 17 at 1:55 PM
feeds.benzinga.com logoMid-Day Market Update: Hasbro Gains On Earnings Beat; PTC Therapeutics Shares Slide
feeds.benzinga.com - October 17 at 12:54 PM
seekingalpha.com logoPTC Therapeutics presents ataluren data in DMD; shares inch up 2%
seekingalpha.com - October 6 at 10:19 AM
seekingalpha.com logoPTC Therapeutics up 17% on licensee Roche's move into mid-stage study in spinal muscular dystrophy
seekingalpha.com - September 30 at 2:01 PM
fool.com logoWhy PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday
www.fool.com - September 20 at 4:19 PM
fool.com logoWhy PTC Therapeutics Shares Skyrocketed 20.6% Today
www.fool.com - September 19 at 9:06 PM
investorplace.com logoHottest Manufacturing Stocks Now – SRPT TANH SORL PTCT
investorplace.com - September 19 at 11:58 AM
seekingalpha.com logo3D Systems introduces path to production, PTC partnership
seekingalpha.com - September 12 at 1:01 PM
fool.com logoWhy PTC Therapeutics Shares Skyrocketed 27% Today
www.fool.com - August 5 at 4:43 PM
seekingalpha.com logoRegulatory review of PTC's Translarna marketing authorization in Europe delayed, renewal expected; shares off 5%
seekingalpha.com - July 25 at 11:55 AM
seekingalpha.com logoPTC Therapeutics up 14% premarket on Translarna deal with England's NHS
seekingalpha.com - July 7 at 9:54 AM
fool.com logoWhy PTC Therapeutics Jumped 10% In May
www.fool.com - June 9 at 6:27 PM
seekingalpha.com logoSarepta buying spreads out to PTC Therapeutics; shares up 5% premarket
seekingalpha.com - May 25 at 8:43 AM
forbes.com logoFriday Sector Leaders: Drugs, Semiconductors
www.forbes.com - May 20 at 2:09 PM
fool.com logoThis Caused a 9.7% Pop in PTC Therapeutics' Shares in April
www.fool.com - May 7 at 9:55 AM
feeds.benzinga.com logoPTC Commences $500 Million Senior Notes Due 2024
feeds.benzinga.com - May 2 at 9:55 AM
thestreet.com logoPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
www.thestreet.com - April 22 at 8:39 PM
feeds.benzinga.com logoWhy NICE Recommendation Is Turning Point For PTC Therapeutics Shares
feeds.benzinga.com - April 18 at 2:24 PM

Social

Chart

PTC (PMTC) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff